TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04542707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: joint manipulation
Description: Thrust manipulation to the spine, hand, and foot

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strength training, bike aerobic training, and yoga exercise
Study: NCT03621774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-assisted CBT-informed Skills Training
Description: mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Contact
Description: The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
Study: NCT02160782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001 (Maralixibat)
Description: LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally once daily during randomized withdrawal period
Study: NCT02250859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101, Minocycline 4% foam
Description: FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
Study: NCT04645888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted tooth surgery
Description: Surgical extraction of İmpacted tooth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted tooth surgery
Description: Surgical extraction of İmpacted tooth
Study: NCT03454685

Intervention type: OTHER
Intervention: without intervention type
Description: Without intervention,this study is just an observational study.

Intervention type: OTHER
Intervention: without intervention type
Description: Without intervention,this study is just an observational study.
Study: NCT04798495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal interdisciplinary rehabilitation programme (HAPPY)
Description: A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
Study: NCT01460589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: timing to initiate the adjuvant chemotherapy
Description: Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: timing to initiate the adjuvant chemotherapy
Description: Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
Study: NCT02828969

Intervention type: OTHER
Group type: OTHER
Intervention: Phone call or physical consultation
Study: NCT02387177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 1
Description: Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 2
Description: Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
Study: NCT02003365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 10 mg
Description: Extended-release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 40 mg
Description: Extended-release formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40 mg
Description: Immediate-release formulation
Study: NCT03418623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GET73
Description: GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
Study: NCT00694915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w
Description: Immunomodulator

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG (Bacillus Calmette-Guerin)
Description: Immunotherapeutic agent
Study: NCT00537238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: 300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: 1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
Study: NCT01054326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Study: NCT00632073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
Study: NCT00954304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 1mg
Description: HM30181AK 1mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 5mg
Description: HM30181AK 5mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 5mg
Description: HM30181AK 5mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 15mg
Description: HM30181AK 15mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK 60mg
Description: HM30181AK 60mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide 2mg
Description: Loperamide 2mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide 2mg
Description: Loperamide 2mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide 2mg
Description: Loperamide 2mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide 2mg
Description: Loperamide 2mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide 2mg
Description: Loperamide 2mg capsule
Study: NCT02292199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS High Frequency
Description: TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS Low Frequency
Description: TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
Study: NCT03107182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Description: Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant RT
Description: Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).
Study: NCT04030650

Intervention type: OTHER
Intervention: Functional analyses
Description: 2-minute walking test 200-metre walking test

Intervention type: OTHER
Intervention: 3D analysis of walking and balance
Description: Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb

Intervention type: OTHER
Intervention: 3D analysis of walking and balance
Description: Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb

Intervention type: OTHER
Intervention: Functional analyses
Description: 400-metre walking test 200-metre walking test
Study: NCT04394611

Intervention type: OTHER
Intervention: Obstetric ultrasound- doppler examination
Description: Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements

Intervention type: OTHER
Intervention: Obstetric ultrasound- doppler examination
Description: Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
Study: NCT03802851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of Prostate (HoLEP)
Description: Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
Study: NCT00214669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE (Professional Asthma Care Education)
Description: Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Led Expert Patient Programme
Description: Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma self management education by a specialist nurse
Description: asthma education and self management, asthma action plans
Study: NCT02340507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice and bread (high GI)
Description: Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice and bread (low GI)
Description: Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
Study: NCT03068598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn watch/Suunto Spartan Ultra watch
Description: The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
Study: NCT03375827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IGCDG
Description: The IGCDG reviews topics of concern for patients with metastatic breast cancer.
Study: NCT03037801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)
Description: IPV physiotherapy 3 times a day
Study: NCT01938872

Intervention type: PROCEDURE
Intervention: paclitaxel eluting balloon angioplasty in below-the-knee lesions
Study: NCT03180697

Intervention type: DIAGNOSTIC_TEST
Intervention: APT MR Imaging
Description: Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
Study: NCT02248415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No pump
Description: In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.

Intervention type: OTHER
Group type: OTHER
Intervention: Pump
Description: In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: after induction of anaesthesia (T0)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: after induction of anaesthesia (T0)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: after arrival at the ICU (T1)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: after arrival at the ICU (T1)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: 4 hours in ICU (T2)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: 4 hours in ICU (T2)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection: the first postoperative day (T3)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: the first postoperative day (T3)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study: NCT02703220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia/oxygen
Description: The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
Study: NCT00721123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
Study: NCT03054753

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Abduction brace wearing time analysis
Description: To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
Study: NCT02128906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 weekly x 7

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT: once daily, M-F, 7 weeks (70 Gy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT: once daily, M-F, 7 weeks (70 Gy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 15 mg/m2 weekly x 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
Study: NCT03473951

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperuricemia
Description: Hyperuricemia vs. normouricemia
Study: NCT00814866

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Adalimumab 40 mg sub-cutaneously every two weeks
Study: NCT03388385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Intravenous Solution
Description: Physiologic saline infusion will be infused in day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Intravenous Solution
Description: Physiologic saline infusion will be infused in day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: Ferric carboxymaltose will be infused in day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject
Description: Ferric carboxymaltose will be infused in day 2.
Study: NCT02420158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-cutaneous vagal nerve electrical stimulation
Study: NCT03894046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam
Description: 1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam
Description: 1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durlobactam
Description: 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durlobactam
Description: 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Treatment for 7 days up to 14 days if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin 500 mg/500 mg
Description: 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/Cilastatin 500 mg/500 mg
Description: 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin 500 mg/500 mg
Description: 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
Study: NCT01526772

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Transoral endoscopy versus transoral endoscopy
Study: NCT03364569

Intervention type: PROCEDURE
Intervention: Tranexamic acid
Description: Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.